We are applying our expertise in genomic profiling to identify elusive cancer-related genetic changes and new biomarker targets across many cancer types. Our advanced cancer genome analysis helps researchers and biopharmaceutical partners accelerate new precision medicine development.
We offer a portfolio of comprehensive genomic profiling assays for precision medicine development.
|OVERVIEW||Broadest liquid biopsy panel||Focused pan-cancer panel that includes guideline-recommended genes||Panel for known or novel gene fusion / splice variant detection||Panel that analyzes genes associated with hereditary cancers|
|NUMBER OF GENES||600 (DNA)||152 (DNA)||88 (RNA)||25 (DNA)|
|TURNAROUND TIME||10 Days||10 Days||10 Days||10 Days|
|REPORT FEATURES||Point mutations, insertions/deletions, copy number gain, copy number loss, rearrangements||Point mutations, insertions/deletions, copy number gain, copy number loss, rearrangements||RNA fusions|
RNA splice variants
|Pathogenic germline variants|
|SENSITIVITY||0.25% down to 0.05%||0.25% down to 0.05%||10 copies||20%|
|DETAILS||About PredicineATLAS™||About PredicineCARE™||About PredicineRNA™||About PredicineHEREDITARY™|
We provide harmonized assays supported by unified quality management systems and workflow in our network of CLIA-certified and CAP-accredited facilities in U.S. and China to support cross-border clinical studies.
Ready to streamline your precision oncology clinical research programs? Submit your information to speak to a team member.